Bristol-myers Squibb Stock News

An analysis of global supply chains and commodity markets in the presence of significant kinetic warfare. Examples of three attractive stocks for the long run, in my view.

To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been.

We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer Bio-Rad Laboratories stock (NYSE: BIO), a life sciences company, given its better growth p

It's nice to have some winners when most stocks aren't performing well.

Bristol-Myers Squibb Co (BMY) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript)

Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.

Bristol Myers Squibb is rapidly becoming a momentum growth stock.

Sanofi (SNY) is developing a subcutaneous formulation of its myeloma drug, Sarclisa. A pivotal study is expected to start in the second half of 2022.

Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.

Pfizer should remain a pharma powerhouse long after the COVID-19 pandemic comes to an end.

Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

RICHMOND, Va., March 15, 2022 (GLOBE NEWSWIRE) -- Virginia Commonwealth University Massey Cancer Center , Medical University of South Carolina Hollings Cancer Center and University of North Carolina Lineberger Comprehensive Cancer Center secured a four-year, $3 million grant from Stand Up To Cancer® (SU2C) that will establish the SU2C Lung Cancer Health Equity Research Team and build on the long-standing community outreach and engagement efforts of these institutions to develop culturally-sensitive, community-informed interventions aimed at reducing lung cancer disparities. This grant is made possible by the support of Bristol Myers Squibb and is a part of SU2C''s Health Equity Initiative , which was announced in 2020 and focuses on increasing diversity in cancer clinical trials, initiating advocacy group collaborations and awareness campaigns, and funding research aimed at improving cancer outcomes and screening rates in medically underserved communities. Black Americans are disproportionately impacted by social determinants of health, which can increase their risk for smoking and limit their access to lung cancer screening and care.